Posted by Michael Wonder on 21 Feb 2024
Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment of adults with locally advanced or metastatic, BRCA mutation positive, HER2 negative breast cancer.
Talazoparib tosylate is recommended for the treatment of adults with locally advanced or metastatic, BRCA mutation positive, HER2 negative breast cancer who have been treated with an anthracycline or a taxane, or both, unless these treatments are not suitable, and endocrine therapy if they have hormone receptor positive breast cancer, unless this is not suitable.
Talazoparib tosylate is only recommended if Pfizer provides it according to the commercial arrangement.
